Nazione: Canada
Lingua: inglese
Fonte: Health Canada
DILTIAZEM HYDROCHLORIDE
APOTEX INC
C08DB01
DILTIAZEM
120MG
CAPSULE (CONTROLLED-DELIVERY)
DILTIAZEM HYDROCHLORIDE 120MG
ORAL
100/500
Prescription
MISCELLANEOUS CALCIUM-CHANNEL BLOCKING AGENTS
Active ingredient group (AIG) number: 0115863004; AHFS:
APPROVED
1997-03-26
_APO-DILTIAZ CD (Diltiazem Hydrochloride) Product Monograph _ _page 1 of 47 _ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-DILTIAZ CD Diltiazem Hydrochloride Controlled Delivery Capsules Controlled Delivery Capsules, 120 mg, 180 mg, 240 mg and 300 mg, Oral Apotex Standard Antihypertensive Agent_ _ Antianginal Agent APOTEX INC 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: SEP 16, 1996 Date of Revision: JUL 24, 2023 Submission Control Number: 272276 _Pr_ _APO-DILTIAZ CD (Diltiazem Hydrochloride) Product Monograph _ _page 2 of 47 _ RECENT MAJOR LABEL CHANGES 2 CONTRAINDICATIONS 07/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ........................................................................................... 2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ..................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................................. 4 1.2 Geriatrics ................................................................................................................................. 4 2 CONTRAINDICATIONS ................................................................................................... 4 4 DOSAGE AND ADMINISTRATION ................................................................................... 5 4.1 Dosing Considerations ........................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment .................................................................. 5 4.4 Administration .......... Leggi il documento completo